RxDoctor Payments Data

Gregory Vorhoff, MD

Cardiovascular Disease · Kenner, LANPI 1003815903

Payments from drug & device makers

$911in general payments, 2019–2025

Across 50 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$161
  • Johnson & Johnson$160
  • E.r. Squibb & Sons, L.L.C.$96
  • Amgen$90
  • Boehringer Ingelheim$86
  • Merck$78
  • plus $238 from 9 others

What the payments were for

  • Food & beverage$911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$911 in reported general payments places this provider in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,365
Medicare patients
215
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban337$298,297
EntrestoSacubitril/Valsartan44$61,306
Repatha SureclickEvolocumab90$59,978
XareltoRivaroxaban41$38,921
Praluent PenAlirocumab47$30,373
MultaqDronedarone Hcl13$10,059
Metoprolol Succinate427$4,171
Carvedilol ErCarvedilol Phosphate13$2,756
Atorvastatin Calcium316$1,923
Ezetimibe136$1,632
Losartan Potassium214$1,623
Amlodipine Besylate251$1,279
Rosuvastatin Calcium156$1,225
Hydrochlorothiazide274$1,211
Hydralazine Hcl96$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$298,297337 claims
NovartisEntresto$161$61,30644 claims
Johnson & JohnsonXarelto$160$38,92141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →